Pharmaceutical Products Companies By Three Year Return
LargestBiggest EarnersMost ProfitableMost LiquidHighly LeveragedTop DividendsCapital-HeavyHighest ValuationLargest Workforce
Three Year Return
| Three Year Return | Efficiency | Market Risk | Exp Return | ||||
|---|---|---|---|---|---|---|---|
| 1 | VKTX | Viking Therapeutics | 0.09 | 5.97 | 0.53 | ||
| 2 | VRNA | Verona Pharma PLC | 0.24 | 4.17 | 0.99 | ||
| 3 | VRTX | Vertex Pharmaceuticals | (0.03) | 1.23 | (0.03) | ||
| 4 | VERA | Vera Therapeutics | 0.10 | 2.95 | 0.29 | ||
| 5 | VYGR | Voyager Therapeutics | (0.11) | 3.26 | (0.35) | ||
| 6 | ELVN | Enliven Therapeutics | 0.07 | 3.37 | 0.24 | ||
| 7 | DMAC | DiaMedica Therapeutics | 0.20 | 3.64 | 0.74 | ||
| 8 | HROWM | Harrow Health, 11875 | 0.08 | 0.59 | 0.05 | ||
| 9 | ENGN | enGene Holdings Common | (0.08) | 5.05 | (0.42) | ||
| 10 | XOMAP | XOMA Corp | 0.05 | 0.67 | 0.03 | ||
| 11 | EPRX | Eupraxia Pharmaceuticals Common | |||||
| 11 | EQ | Equillium | 0.09 | 5.16 | 0.46 | ||
| 12 | ME | 23Andme Holding Co | (0.01) | 4.51 | (0.06) | ||
| 13 | NUVB-WS | NUVATION BIO INC | |||||
| 13 | VERU | Veru Inc | (0.08) | 3.74 | (0.30) | ||
| 14 | DRMA | Dermata Therapeutics | 0.03 | 17.93 | 0.46 | ||
| 15 | DRRX | Durect | 0.03 | 4.79 | 0.15 | ||
| 16 | DRUG | Bright Minds Biosciences | 0.05 | 6.78 | 0.31 | ||
| 17 | CDIOW | Cardio Diagnostics Holdings | 0.19 | 211.05 | 40.11 | ||
| 18 | SABSW | SAB Biotherapeutics | 0.28 | 280.27 | 77.15 |
The analysis above is based on a 90-day investment horizon and a default level of risk. Use the Portfolio Analyzer to fine-tune all your assumptions. Check your current assumptions here.
Tree Year Return shows the total annualized return generated from holding a fund or ETFs for the last three years. The return measure includes capital appreciation, losses, dividends paid, and all capital gains distributions. This return indicator is considered by many investors to be solid measures of fund mid-term performance. Although Three Year Fund Return indicator can give a sense of overall fund mid-term potential, it is recommended to compare fund performances against other similar funds, ETFs, or market benchmarks for the same 3 year interval.